Achieved $30 million milestone from Roche and Genentech for delivering a whole-genome map of microglial immune cells—the ...

Q3 2025 Management View Christopher Gibson, Co-Founder and CEO, announced, "beginning January 1, the amazing Najat Khan is going to take over the role of CEO, President and Director of Recursion." ...

AI-based drug developer Recursion’s stock barely moved Wednesday, then dropped Thursday and Friday, after reporting mixed third quarter results, setting the stage for future pipeline announcements—and ...

A patchwork of internet communities is devoted to the project of ‘awakening’ more digital companions through arcane and enigmatic prompts.

B y any measure, there is an enormous number of programming languages. Some lists contain hundreds, while the Historical ...

The Dark Enlightenment of AI has turned efficiency into ideology. Here’s how it’s reshaping brands, leadership, and the ...

Recursion Pharmaceuticals (RXRX) ended the recent trading session at $5.75, demonstrating a -5.89% change from the preceding day's closing price. The stock's change was less than the S&P 500's daily ...

Management believes it can drastically cut down the time and cost to bring drugs to market. The company is involved with multiple clinical trials, but none of them are in late stages just yet. Its ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...

Brevis, a zero-knowledge verifiable computing platform, released the ProverNet whitepaper on Nov. 17, introducing a ...